https://www.selleckchem.com/pr....oducts/NVP-TAE684.ht
890; 95% CI 0.846-0.936; p 0.0001), CVI (HR 0.873; 95% CI 0.770-0.991; p = 0.0352), and CrVD (HR 0.869; 95% CI 0.824-0.917; p 0.0001). CVD risk was significantly decreased in patients using ADT for over 2years. CVI and CrVD risks were significantly lower in men using ADT for over 3years. This study demonstrated that ADT may reduce the risk of CVD, CVI, and CrVD, and ADT duration is associated with this risk reduction. This study demonstrated that ADT may reduce the risk of CVD, CVI, and CrVD, and ADT duration is associated
Like
Comment
Share
